A patient in California is now the first person in the U.S. to use an experimental treatment secured through the Right to Try Act, reports Regulatory Focus.
President Donald Trump signed the Right to Try Act into federal law in May 2018. The law gives patients with life-threatening conditions the opportunity to access experimental treatments without FDA authorization.
The patient was diagnosed with an aggressive form of brain cancer and began using the experimental treatment ERC-1671 at University of California, Irvine in November 2018. ERC-USA is developing the experimental drug, which is currently in phase 2 clinical trials. The patient sought to access the drug through the Right to Try Act after failing to qualify for an ongoing clinical trial.